Xarelto is an anti-coagulant primarily used to reduce the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation, to treat deep vein thrombosis (“DVT”), to treat pulmonary embolisms (“PE”), and/or to reduce the risk of recurrence of DVT and/or PE.
Xarelto was approved by the Food and Drug Administration (“FDA”) on July 1, 2011 to reduce the risk of blood clots, DVT, and PE following knee and hip replacement surgery. It was approved as a blood thinner, it has been used as a replacement for Wafarin and Coumadin and has been marketed as more convenient than other alternatives.
Nothing is more stressful than a trip to the Emergency Room when you or a loved one has been injured or has suffered a medical emergency. All too often, medical mistakes happen, which unexpectedly make this situation even worse. This type of medical malpractice occurs due to such factors as an under-staffed or ill equipped facility. Medical malpractice in an emergency room setting can occur in a number of different situations including:
- Internal Bleeding
- Brain Hemorrhaging
- Hemorrhagic Stroke
- Rectal Bleeding
- Intestinal Bleeding
- Death due to Uncontrolled Internal Bleeding.
- No fall precautions.
- Laboratory errors.
- Surgical errors
Davant & Associates is currently involved in litigation against Bayer, and Janessen Pharmaceuticals, a subsidiary of Johnson & Johnson with regard to a Client who suffered a hemorrhagic stroke while taking it following a hip replacement surgery. We are currently investigating cases involving patients who were injured or who died due to uncontrolled internal bleed while taking Xarelto.
We will have your case reviewed as quickly as possible, and let you know whether we believe you have a case we are willing to pursue, usually within days of obtaining relevant medical records. Please contact Davant & Associates for a no obligation free case evaluation.